Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukotriene activity modulation in asthma

S L Spector1

  • 1Department of Medicine, UCLA School of Medicine, USA.

Drugs
|September 1, 1997
PubMed
Summary
This summary is machine-generated.

Antileukotriene agents effectively treat asthma by blocking inflammatory mediators. These medications are well-tolerated and show promise in managing airway obstruction and inflammation in asthma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leukotrienes and the mechanism by which the LTRAs block their asthma-related effects.

Postgraduate medicine·2009
Same author

Safety of antileukotriene agents in asthma management.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2001
Same author

Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2000
Same author

Lung disease.

Clinical allergy and immunology·2000
Same author

Using antileukotrienes in asthma therapy.

Indian journal of medical sciences·2000
Same author

Using antileukotrienes in asthma therapy.

Indian journal of medical sciences·2000
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Biochemistry
  • Immunology
  • Pharmacology

Background:

  • Leukotrienes are key inflammatory mediators derived from arachidonic acid.
  • The 5-lipoxygenase pathway synthesizes various leukotrienes with distinct biological activities.
  • Leukotrienes contribute to asthma by causing bronchoconstriction, mucus secretion, and airway tissue fluid extravasation.

Purpose of the Study:

  • To review the development and efficacy of antileukotriene agents for inflammatory diseases.
  • To evaluate the role of antileukotriene agents in managing asthma.
  • To discuss the therapeutic potential of leukotriene synthesis inhibitors and receptor antagonists.

Main Methods:

  • Review of preclinical and clinical trial data on antileukotriene agents.
  • Analysis of the mechanisms of action for leukotriene receptor antagonists and synthesis inhibitors.

Related Experiment Videos

  • Examination of clinical outcomes in asthma patients treated with antileukotriene medications.

    • Main Results:

    • Antileukotriene agents successfully attenuate responses to various asthma triggers, including inhaled leukotrienes, cold air, exercise, aspirin, and allergens.
    • These agents have demonstrated significant efficacy in clinical trials for asthma management.
    • Antileukotriene therapies have been associated with a favorable safety profile, with no serious adverse effects reported.

    Conclusions:

    • Antileukotriene agents are well-tolerated and effective in treating asthma.
    • The recent FDA approval of new antileukotriene medications offers further opportunities to assess their clinical utility.
    • These agents represent a valuable therapeutic option for modulating airway inflammation and obstruction in asthma.